The Etiology of New-onset Status Epilepticus
Completed
- Conditions
- Status Epilepticus
- Registration Number
- NCT05647525
- Lead Sponsor
- Jie Liu
- Brief Summary
This study will help to identify the causes of new epilepsy and provide a basis for the development of a rational and standardized diagnosis and treatment plan to reduce the rate of disability and death.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- Clinical diagnosis of Status Epilepticus
- Sign the informed consent form
Exclusion Criteria
- Patients with previous epilepsy
- Missing information such as basic information and treatment history
- Long-term smoking, alcohol and drug abuse
- Pregnant and breastfeeding women
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Death 2021-12--2022-12
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie new-onset status epilepticus in NCT05647525?
How does the observational study design of NCT05647525 compare to interventional trials in epilepsy management?
What biomarkers are associated with status epilepticus prognosis in Sichuan Provincial People's Hospital studies?
What adverse events are commonly reported in status epilepticus observational cohorts and how are they managed?
How do findings from NCT05647525 contribute to the development of targeted therapies for refractory status epilepticus?
Trial Locations
- Locations (1)
Jie Liu
🇨🇳Chengdu, Sichuan, China
Jie Liu🇨🇳Chengdu, Sichuan, China